论文部分内容阅读
目的:观察FOLFOX6方案与FOLFIRI方案交替治疗晚期结肠癌的临床疗效。方法:98例晚期结肠癌患者进行FOLFOX6方案与FOLFIRI方案交替治疗,第1疗程按FOLFOX6方案给药;第2疗程按FOLFIRI方案给药;2个方案14天重复1次,2次为1疗程,每2疗程复查,评价疗效。化疗4~6疗程,出现进展停止使用。结果:总有效率为60.2%,对98例患者进行了随访。TTP为9.8个月,1年生存期达80例(81.6%)。毒副反应主要是恶心、呕吐,骨髓抑制,末梢神经炎、迟发性腹泻,乙酰胆碱综合征,脱发等。结论:晚期结肠癌应用FOLFOX6与FOLFIRI交替方案治疗,减少了患者发生耐药性的机会和毒副反应。
Objective: To observe the clinical efficacy of FOLFOX6 regimen and FOLFIRI regimen in the treatment of advanced colon cancer. Methods: 98 patients with advanced colon cancer were treated with FOLFOX6 regimen and FOLFIRI regimen alternately. The first course was given by FOLFOX6 regimen. The second regimen was administered by FOLFIRI regimen. The two regimens were repeated 14 days, 1 second regimen, Review every 2 courses, evaluate the curative effect. 4 to 6 courses of chemotherapy, there is progress to stop using. Results: The total effective rate was 60.2%. 98 patients were followed up. TTP was 9.8 months, 1-year survival of 80 cases (81.6%). Toxic and side effects are mainly nausea, vomiting, bone marrow suppression, peripheral neuritis, delayed diarrhea, acetylcholine syndrome, hair loss and so on. Conclusion: The treatment of advanced colorectal cancer with FOLFOX6 and FOLFIRI alternates to reduce the chances of patients developing drug resistance and toxic side effects.